Marizyme (MRZM) 10-Q 6 May 21 2021 Q1 Quarterly report Financial data

Document and Entity Information

Document and Entity Information - shares	3 Months Ended
	Mar. 31, 2021	May 06, 2021
Cover [Abstract]
Entity Registrant Name	MARIZYME INC
Entity Central Index Key	0001413754
Document Type	10-Q
Document Period End Date	Mar. 31, 2021
Amendment Flag	false
Current Fiscal Year End Date	--12-31
Entity Reporting Status Current	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business Flag	true
Entity Emerging Growth Company	true
Entity Ex Transition Period	true
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		35,928,188
Document Fiscal Period Focus	Q1
Document Fiscal Year Focus	2021

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets - USD ($)	Mar. 31, 2021	Dec. 31, 2020
Current assets
Cash	$ 834,957	$ 2,902,762
Accounts receivable	35,783	40,585
Prepaid expense	63,100	106,390
Inventory	44,640	56,340
Total current assets	978,480	3,106,077
Fixed assets, net	4,122	7,122
Operating lease right-of-use assets, net	1,257,929	1,317,830
Intangible assets, net	41,927,293	42,278,211
Prepaid royalties, non-current	340,969	344,321
Deposits	30,000	30,000
Total assets	44,538,793	47,083,561
Current liabilities
Accounts payable and accrued expenses	445,069	478,103
Operating lease obligations, current portion	304,114	243,292
Total current liabilities	749,183	721,395
Non-current liabilities
Operating lease obligations, non-current portion	978,148	1,074,538
Total non-current liabilities	978,148	1,074,538
Total liabilities	1,727,331	1,795,933
Commitments and contingencies (see Note 5)
Stockholders' equity
Preferred stock, $0.001 par value, 25,000,000 shares authorized, 0 shares issued and outstanding as of March 31, 2021 and December 31, 2020
Common stock, par value $0.001, 75,000,000 shares authorized, 35,928,188 shares issued and outstanding as of March 31, 2021 and December 31, 2020	35,928	35,928
Additional paid in capital	82,411,719	82,077,334
Accumulated deficit	(39,636,185)	(36,825,634)
Total stockholders' equity	42,811,462	45,287,628
Total liabilities and stockholders' equity	$ 44,538,793	$ 47,083,561

Condensed Consolidated Balanc_2

Condensed Consolidated Balance Sheets (Parenthetical) - $ / shares	Mar. 31, 2021	Dec. 31, 2020
Statement of Financial Position [Abstract]
Preferred stock, par value	$ 0.001	$ 0.001
Preferred stock, shares authorized	25,000,000	25,000,000
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0
Common stock, par value	$ 0.001	$ 0.001
Common stock, shares authorized	75,000,000	75,000,000
Common stock, shares issued	35,928,188	35,928,188
Common stock, shares outstanding	35,928,188	35,928,188

Condensed Consolidated Statemen

Condensed Consolidated Statements of Operations (Unaudited) - USD ($)	3 Months Ended
	Mar. 31, 2021	Mar. 31, 2020
Income Statement [Abstract]
Revenue	$ 73,952
Operating expenses
Direct costs of revenue	30,842
Professional fees	659,058	108,019
Salary expenses	1,036,457
Stock-based compensation	367,718	221,058
Depreciation and amortization	416,595
Other general and administrative expenses	373,833	142,293
Total operating expenses	2,884,503	471,370
Total operating loss	(2,810,551)	(471,370)
Net loss	$ (2,810,551)	$ (471,370)
Loss per share - basic and diluted	$ (0.08)	$ (0.02)
Weighted average number of shares of common stock - basic and diluted	35,928,188	19,887,021

Condensed Consolidated Statem_2

Condensed Consolidated Statements of Changes in Stockholders' Equity (Unaudited) - USD ($)	Preferred Stock [Member]	Common Stock [Member]	Additional Paid-in Capital [Member]	Treasury Stock [Member]	Accumulated Deficit [Member]	Total
Balance at Dec. 31, 2019		$ 19,859	$ 59,319,594	$ (16,000)	$ (30,980,581)	$ 28,342,872
Balance, shares at Dec. 31, 2019		19,858,939
Common stock issued		$ 125	124,875			125,000
Common stock issued, shares		125,000
Stock-based compensation expense			221,058			221,058
Net loss					(471,370)	(471,370)
Balance at Mar. 31, 2020		$ 19,984	59,665,527	(16,000)	(31,451,951)	28,217,560
Balance, shares at Mar. 31, 2020		19,983,939
Balance at Dec. 31, 2020		$ 35,928	82,077,334		(36,825,634)	45,287,628
Balance, shares at Dec. 31, 2020		35,928,188
Stock-based compensation expense			334,385			334,385
Net loss					(2,810,551)	(2,810,551)
Balance at Mar. 31, 2021		$ 35,928	$ 82,411,719		$ (39,636,185)	$ 42,811,462
Balance, shares at Mar. 31, 2021		35,928,188

Condensed Consolidated Statem_3

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)	3 Months Ended
	Mar. 31, 2021	Mar. 31, 2020
Cash flows from operating activities:
Net loss	$ (2,810,551)	$ (471,370)
Adjustments to reconcile net loss to net cash used in operations:
Depreciation expense	62,901
Amortization expense	353,694
Stock-based compensation - stock options	334,385	346,058
Stock-based compensation - restricted common stock	33,333
Change in operating assets and liabilities:
Accounts receivable	4,802
Prepaid expense	43,290
Inventory	11,700
Accounts payable and accrued expenses	(98,584)	125,282
Net cash used in operating activities	(2,065,030)	(30)
Cash flows used in investing activities:
Purchase of intangible assets	(2,775)
Net cash used in investing activities	(2,775)
Net decrease in cash	(2,067,805)	(30)
Cash at beginning of period	2,902,762	90
Cash at end of period	834,957	60
Supplemental disclosure of cash flow information:
Cash paid for interest
Cash paid for taxes

Organization and Description of

Organization and Description of Business	3 Months Ended
	Mar. 31, 2021
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Organization and Description of Business	NOTE 1 – ORGANIZATION AND DESCRIPTION OF BUSINESS Overview Marizyme, Inc., a Nevada corporation formerly known as GBS Enterprises Incorporated (the “Company” or “Marizyme”), conducted its primary business through its majority owned subsidiary, GBS Software AG (“GROUP”), a German-based public-company. By December 31, 2016, the Company had sold the controlling interest in GROUP and other subsidiaries, keeping only a minority interest in GROUP. On March 21, 2018, the Company formed a wholly owned subsidiary named Marizyme, Inc., a Nevada corporation, and merged with it, effectively changing the Company’s name to Marizyme, Inc. On June 1, 2018, the Company exchanged the shares of GROUP and all the intercompany assets and liabilities for 100% of the shares of X-Assets Enterprises, Inc, a Nevada Corporation. As part of a type-D business restructuring on September 5, 2018, the Company then distributed the X-Assets shares to its stockholders on a 1 for 1 basis. Beginning after the X-Assets share distribution, Marizyme refocused on the life sciences and began to seek technologies to acquire. On September 12, 2018, the Company consummated an asset acquisition with ACB Holding AB, Reg. No. 559119-5762, a Swedish corporation to acquire all rights, title, and interest in their Krillase technology in exchange for 16.98 million shares of Common Stock. Krillase is a naturally occurring enzyme that acts to break protein bonds and has applications in dental care, wound healing, and thrombosis. On December 15, 2019, the Company entered into a contingent asset purchase agreement (the “Agreement”), as amended on March 31, 2020 and May 29, 2020, with Somahlution, LLC, Somahlution, Inc., and Somaceutica, LLC, companies duly organized under the laws of Delaware (collectively, “Somah”) to acquire all of the assets and none of the liabilities of Somah (the “Acquisition”), including DuraGraft®, a one-time intraoperative vascular graft treatment for use in vascular and bypass surgeries that maintains endothelial function and structure, and other related properties. On July 30, 2020, the Company and Somah entered into Amendment No. 3 to the Agreement which finalized this Agreement. Pursuant to the terms of this amendment, it was agreed that, as part of the Acquisition, the Company would acquire the outstanding capital stock of Somahlution, Inc., held by Somahlution, LLC, rather than the assets of Somahlution, Inc. This change to the Agreement was made to accommodate the European Union (“EU”) requirements with respect to the future manufacturing under Somahlution, Inc. of CE marked products for sale in the EU. On September 25, 2020, the Company formed Somaceutica, Inc., a Florida corporation. On March 31, 2021, the Company formed Marizyme Sciences, Inc., a Florida corporation. The Company’s common stock, $0.001 par value per share (the “Common Stock”), is currently quoted on the OTC Markets QB Tier under the ticker symbol “MRZM.” Change in Management and the Board of Directors On September 1, 2020, Nicholas DeVito resigned as the Company’s interim chief executive officer and chief financial officer. On September 1, 2020, Bruce Harmon was appointed as the Company’s chief financial officer. On September 1, 2020, James Sapirstein, a director of the Company, became the Company’s interim chief executive officer. On October 30, 2020, Dr. William Hearl was appointed as a Director on the Company’s board of directors. On November 1, 2020, Dr. Neil J. Campbell was appointed as the Company’s chief executive officer, president, and director. On November 1, 2020, James Sapirstein relinquished his role as interim chief executive officer. On December 1, 2020, Dr. Steven Brooks was appointed as the Company’s Chief Medical Officer and Executive Vice President of Medical and Regulatory Affairs. On December 2, 2020, Dr. Donald Very, Jr. was appointed as the Company’s Executive Vice President of Research and Development. On January 16, 2021, Roger Schaller was appointed as the Company Executive Vice President of Commercial Operations. On January 29, 2021, Amy Chandler was promoted to Executive Vice President of Regulatory and Quality Affairs. On February 3, 2021, Julie Kampf was appointed as a Director on the Company’s board of directors. On February 22, 2021, Dr. Vithal Dhaduk was appointed as a Director on the Company’s board of directors. On March 18, 2021, Dr. Neil Campbell resigned as Chief Executive Officer, President and Director. On March 19, 2021, James Sapirstein was appointed as Interim Chief Executive Officer. On April 2, 2021, Dr. Satish Chandran was terminated as Chief Technology Officer.

Going Concern

Going Concern	3 Months Ended
	Mar. 31, 2021
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Going Concern	NOTE 2 - GOING CONCERN The accompanying unaudited condensed consolidated financial statements and the factors within it, have been prepared on a going concern basis, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business and the ability of the Company to continue as a going concern for a reasonable period of time. The Company had a net loss of $2,810,551 and cash used in operating activities of $2,065,030 for the three months ended March 31, 2021. As of March 31, 2021, the Company had a working capital surplus of $229,297, and accumulated deficit of $39,636,185. The Company’s continuation as a going concern is dependent upon its ability to generate revenues and its ability to continue receiving investment capital and loans from third parties to sustain its current level of operations. These factors raise substantial doubt about the Company’s ability to continue as a going concern. The Company is in the process of securing working capital from investors for common stock, convertible notes payable, and/or strategic partnerships. No assurance can be given that the Company will be successful in these efforts. The financial statements do not include any adjustments relating to the recoverability and classification of recorded asset amounts or the amounts and classification of liabilities that might be necessary should the Company be unable to continue as a going concern.

Summary of Significant Accounti

Summary of Significant Accounting Policies	3 Months Ended
	Mar. 31, 2021
Accounting Policies [Abstract]
Summary of Significant Accounting Policies	NOTE 3 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Basis of Presentation The Company follows the accrual basis of accounting in accordance with generally accepted accounting principles in the United States of America (U.S. GAAP). The unaudited condensed consolidated financial statements of the Company for the three month periods ended March 31, 2021 and 2020 have been prepared in accordance with accounting principles generally accepted in the United States of America for interim financial information and pursuant to the requirements for reporting on Form 10-Q and Regulation S-K. Accordingly, they do not include all the information and footnotes required by accounting principles generally accepted in the United States of America for complete financial statements. However, such information reflects all adjustments (consisting solely of normal recurring adjustments), which are, in the opinion of management, necessary for the fair presentation of the financial position and the results of operations. Results shown for interim periods are not necessarily indicative of the results to be obtained for a full fiscal year. The balance sheet information as of December 31, 2020 was derived from the audited financial statements included in the Company’s financial statements as of and for the year ended December 31, 2020 included in the Company’s Annual Report on Form 10-K filed with the Securities and Exchange Commission (the “SEC”) on April 15, 2021. These financial statements should be read in conjunction with that report. Principles of Consolidation The accompanying unaudited condensed consolidated financial statements include all of the accounts of the Company and its wholly owned subsidiaries, Somahlution, Inc. (“Somahlution”), Somaceutica, Inc. (“Somaceutica”) and Marizyme Sciences, Inc. (“Marizyme Sciences”). All significant intercompany balances and transactions have been eliminated. Use of Estimates The preparation of the unaudited condensed consolidated financial statements in accordance with U.S. GAAP requires management to make use of certain estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities as of the date of the consolidated financial statements and the reported amounts of revenue and expenses during the reported periods. The Company bases its estimates on historical experience and on various other assumptions that management believes are reasonable under the circumstances, the results of which form the basis for making judgments about carrying values of assets and liabilities that are not readily apparent from other sources. Actual results could differ from those estimates. Significant estimates are related to the allocation of the purchase price in a business combination to the underlying assets and liabilities, allowance for doubtful accounts, recoverability of long-term assets including intangible assets and goodwill, amortization expense, inventory valuation, valuation of warrants, stock-based compensation, and deferred tax valuations. Business Combinations The Company accounts for business acquisitions using the acquisition method of accounting based on Accounting Standards Codification (“ASC”) 805 — Business Combinations, which requires recognition and measurement of all identifiable assets acquired and liabilities assumed at their fair value as of the date control is obtained. The Company determines the fair value of assets acquired and liabilities assumed based upon its best estimates of the acquisition-date fair value of assets acquired and liabilities assumed in the acquisition. Goodwill represents the excess of the purchase price over the fair value of the net tangible and identifiable intangible assets acquired. Subsequent adjustments to fair value of any contingent consideration are recorded to the Company’s consolidated statements of operations. Stock-Based Compensation Stock-based compensation expense is recorded in accordance with FASB ASC Topic 718, Compensation – Stock Compensation, for stock and stock options awarded in return for services rendered. The expense is measured at the grant-date fair value of the award and recognized as compensation expense on a straight-line basis over the service period, which is the vesting period. The Company estimates forfeitures that it expects will occur and records expense based upon the number of awards expected to vest. The fair value of each option is estimated on the date of grant using the Black-Scholes option pricing model. Cash Equivalents The Company considers all highly liquid investments with an original maturity of three months or less when purchased to be cash equivalents. At March 31, 2021 and December 31, 2020, the Company had no cash equivalents. Reclassifications Certain amounts in the prior year’s unaudited condensed consolidated financial statements have been reclassified to conform to the current period presentation. These reclassifications had no effect on reported losses, total assets, or stockholders’ equity as previously reported. The reclassifications were for the Statement of Operation which combined its expenses into two categories whereas, for comparison purposes for the three months ended March 31, 2021 to March 31, 2020, professional fees and stock-based compensation was segregated. Allowance for Doubtful Accounts The Company establishes an allowance for doubtful accounts to ensure trade and notes receivable are not overstated due to non-collectability. The Company’s allowance is based on a variety of factors, including age of the receivable, significant one-time events, historical experience, and other risk considerations. The Company did not have an allowance at March 31, 2021 or December 31, 2020. The Company did not record any bad debt expense in each of the three months ended March 31, 2021 and 2020. Inventory Inventory consisted of primarily finished goods and is valued at the lower of cost or net realizable value. Inventory is held in a third-party warehouse in foreign countries. Cost is determined using the FIFO method. The Company decreases the value of inventory for estimated obsolescence equal to the difference between the cost of inventory and the estimated market value, based upon an aging analysis of the inventory on hand, specifically known inventory-related risks, and assumptions about future demand and market conditions. The Company has determined that no inventory reserve was necessary as of March 31, 2021 and December 31, 2020. Fair Value of Financial Instruments The Company measures its financial assets and liabilities in accordance with FASB ASC 820 (the “Fair Value Topic”). For certain of our financial instruments, including cash, accounts payable, accrued expenses, and short-term loans the carrying amounts approximate fair value due to their short maturities. We follow accounting guidance for financial and non-financial assets and liabilities. This standard defines fair value, provides guidance for measuring fair value and requires certain disclosures. This standard does not require any new fair value measurements, but rather applies to all other accounting pronouncements that require or permit fair value measurements. This guidance does not apply to measurements related to share-based payments. This guidance discusses valuation techniques, such as the market approach (comparable market prices), the income approach (present value of future income or cash flow), and the cost approach (cost to replace the service capacity of an asset or replacement cost). The guidance utilizes a fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value into three broad levels. The following is a brief description of those three levels: Level 1: Observable inputs such as quoted prices (unadjusted) in active markets for identical assets or liabilities. Level 2: Inputs other than quoted prices that are observable, either directly or indirectly. These include quoted prices for similar assets or liabilities in active markets and quoted prices for identical or similar assets or liabilities in markets that are not active. Level 3: Unobservable inputs in which little or no market data exists, therefore developed using estimates and assumptions developed by us, which reflect those that a market participant would use. The Company had no assets or liabilities measured at fair value on a recurring basis at March 31, 2021 and December 31, 2020. Fixed Assets Fixed assets are recorded at cost. Expenditures for major additions and betterments are capitalized. Maintenance and repairs are charged to operations as incurred. Depreciation is computed by the straight-line method over the assets estimated useful life. Upon the sale or retirement of property and equipment, the related cost and accumulated depreciation are removed from the accounts and any gain or loss is reflected in consolidated statements of operations. Classification Estimated Useful Lives Equipment 5 to 7 years Furniture and fixtures 4 to 7 years Intangible Assets Costs incurred to file patent applications and acquired intangibles are capitalized when the Company believes that there is a high likelihood that the patent will be issued and there will be future economic benefit associated with the patent. These costs will be amortized on a straight-line basis over a 20-year life from the date of patent filing. All costs associated with abandoned patent applications are expensed. In addition, the Company will review the carrying value of patents for indicators of impairment on a periodic basis and if it determines that the carrying value is impaired, it values the patent at fair value. As of March 31, 2021, $122,746 has been capitalized for patents which have not been amortized. Impairment of Long-lived Assets The Company follows ASC 360 for its long-lived assets. The Company’s long-lived assets, such as intellectual property, are required to be reviewed for impairment annually, or whenever events or changes in circumstances indicate that the carrying amount of the asset may not be recoverable. The Company assesses the recoverability of its long-lived assets by comparing the projected undiscounted net cash flows associated with the related long-lived asset or group of long-lived assets over their remaining estimated useful lives against their respective carrying amounts. Impairment, if any, is based on the excess of the carrying amount over the fair value of those assets. Fair value is generally determined using the asset’s expected future discounted cash flows or market value, if readily determinable. If long-lived assets are determined to be recoverable, but the newly determined remaining estimated useful lives are shorter than originally estimated, the net book values of the long-lived assets are depreciated over the newly determined remaining estimated useful lives. The Company determined that there were no impairments of long-lived assets at March 31, 2021 and December 31, 2020. Revenue Recognition We recognize revenue under Accounting Standards Codification (“ASC”) 606, Revenue from Contracts with Customers, (“ASC 606”). The core principle of the revenue standard is that a company should recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which we expect to be entitled in exchange for those goods or services. We only apply the five-step model to contracts when it is probable that we will collect the consideration to which we are entitled in exchange for the goods and services transferred to the customer. The following five steps are applied to achieve that core principle: Step 1: Identify the contract with the customer Step 2: Identify the performance obligations in the contract Step 3: Determine the transaction price Step 4: Allocate the transaction price to the performance obligations in the contract Step 5: Recognize revenue when the company satisfies a performance obligation We have identified one performance obligation which is related to our DuraGraft product sales for our Distribution Partner channel, we recognize revenue for product sales at the time of delivery of the product to our Distribution Partner (customer). The customer is invoiced, and Payment Terms are Net 30. As our products have an expiration date, if a product expires before use, we will replace the product on the shelf at no charge. Revenue disaggregation for three months ended March 31, 2021 amount to $54,319 in Spain, $6,730 in Singapore, $8,656 in Switzerland and $4,247 in India. In the transaction that acquired the assets of Somahlution, LLC, the Company determined that the CE mark for Europe must be in Marizyme, Inc. in order for Somahlution, Inc. to bill revenue and receive the payments accordingly. The Company has filed in Europe for the CE mark to be in Marizyme, Inc. but, until the time it is approved by the Notified Body, BSI (British Standards Institution), which is projected for May 2021, Somahlution, LLC provides the billing and receiver of funds. On a periodical basis, the cash received is transferred to Somahlution, Inc. Direct Cost of Revenue Cost of sales includes the actual cost of merchandise sold; the cost of transportation of merchandise from our third-party vendor to our distributer. Net Income (Loss) per Share The Company computes basic and diluted income (loss) per share amounts pursuant to ASC 260 of the FASB Accounting Standards Codification. Basic loss per share is computed by dividing net loss available to common stockholders, by the weighted average number of shares of common stock outstanding during the period, excluding the effects of any potentially dilutive securities. Diluted loss per share is computed by dividing net loss available to common stockholders by the diluted weighted average number of shares of common stock during the period. The diluted weighted average number of common shares outstanding is the basic weighted number of shares adjusted as of the first day of the year for any potentially diluted debt or equity. The following is a reconciliation of basic and diluted earnings (loss) per common share for the three months ended March 31, 2021 and 2020: For the Three Months Ended March 31, 2021 2020 Basic and diluted loss per common share Numerator: Net loss available to common shareholders $ (2,846,119 ) $ (471,370 ) Denominator: Weighted average common shares outstanding 35,928,188 19,887,021 Basic and diluted loss per common share $ (0.08 ) $ (0.02 ) Income Taxes The Company accounts for income taxes in accordance with FASB ASC 740, “Income Taxes.” Deferred tax assets and liabilities are recognized for the future tax consequences attributable to temporary differences between the financial statements carrying amounts of existing assets and liabilities and loss carryforwards and their respective tax bases. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income (loss) in the years in which those temporary differences are expected to be recovered or settled. The effect of a change in tax rules on deferred tax assets and liabilities is recognized in operations in the year of change. A valuation allowance is recorded when it is “more likely-than-not” that a deferred tax asset will not be realized. Tax benefits of uncertain tax positions are recognized only if it is more likely than not that the Company will be able to sustain a position taken on an income tax return. The Company has no liability for uncertain tax positions as of March 31, 2021 and December 31, 2020. Interest and penalties, if any, related to unrecognized tax benefits would be recognized as interest expense. The Company does not have any accrued interest or penalties associated with unrecognized tax benefits, nor was any significant interest expense recognized during the three months ended March 31, 2021 and 2020. Segment Information In accordance with the provisions of ASC 280-10, “Disclosures about Segments of an Enterprise and Related Information,” the Company is required to report financial and descriptive information about its reportable operating segments. The Company has one operating segment as of March 31, 2021 and December 31, 2020. Effect of Recent Accounting Pronouncements Recently Issued Accounting Standards Not Yet Adopted The Company has reviewed all recently issued, but not yet adopted, accounting standards, in order to determine their effects, if any, on its results of operations, financial position or cash flows. Based on that review, the Company believes that no other pronouncements will have a significant effect on its consolidated financial statements. Concentration of Credit Risk The Company places its temporary cash investments with financial institutions insured by the FDIC. The Company has amounts over insured limits. Amounts on deposit may at times exceed the FDIC insurance limit. The Company has not experienced any losses in such accounts. Customer Concentrations For the three months ended March 31, 2021, four customers/distributors selling to end customers made up 100% of the revenues. As of March 31, 2021, three customers/distributors made up 100% of accounts receivable. Research and Development All research and development costs, payments to laboratories and research consultants are expensed when incurred.

Lease

Lease	3 Months Ended
	Mar. 31, 2021
Leases [Abstract]
Lease	NOTE 4 – LEASE Effective January 1, 2020, the Company adopted the provision of Accounting Standards Update (“ASU”) 2016-02, Leases (Topic 842). The provisions of this ASU require the Company to record a right-of-use asset and related lease liability related to their leases. The Company leases its administrative office and laboratories under an operating lease agreement. The Company entered into an agreement in December 2020 for approximately 8,500 square feet which is for a five-and-one-half year period. The base rent is $10,817 per month. In addition, the Company is obligated to pay monthly operating expenses of approximately $12,000 per month. The lease included incentives of waived base rent for certain periods. The base rent will increase by 2.5% for the second year through the end of the term. Right-Of-Use Asset and Lease Liability: The Company’s consolidated balance sheets reflect the value of the right-of-use asset and related lease liability. This value was calculated based on the present value of the remaining base rent lease payments. The discount rate used was 3.95% which is the average commercial interest available at the time. As a result, the value of the right-of-use asset and related lease liability is as follows: March 31, December 31, 2021 2020 Right-of-use asset $ 1,257,929 $ 1,317,830 Total lease liability $ 1,282,262 $ 1,317,830 Less: Current portion 304,114 243,292 Lease liability, net of current portion $ 978,148 $ 1,074,538 The maturities of the lease liabilities are as follows as of March 31, 2021 for the periods ended December 31: 2021 $ 156,748 2022 277,142 2023 277,142 2024 277,142 2025 277,142 Thereafter 130,950 Total lease payments 1,396,266 Less: Present value discount (114,004 ) Total $ 1,282,262 For the three months ended March 31, 2021, operating cash flows paid in connection with operating leases amounted to $35,568.

Acquisitions

Acquisitions	3 Months Ended
	Mar. 31, 2021
Business Combinations [Abstract]
Acquisitions	NOTE 5 – ACQUISITIONS Krillase On September 12, 2018, the Company consummated an asset acquisition with ACB Holding AB, Reg. No. 559119-5762, a Swedish corporation to acquire all right, title and interest in their Krillase technology in exchange for 16.98 million shares of common stock. Krillase is a naturally occurring enzyme that acts to break protein bonds and has applications in wound debridement, would healing, dental care and thrombosis. The transaction was recorded at the fair value of the shares, $28,600,000. No amortization has been recorded as all of the patents are not yet in a position to produce cash flows. The Company anticipates Krillase being placed into service in 2023. The Company has evaluated this asset for impairment and has determined that due to COVID-19 delaying the next steps for this technology, along with the associated value of the research and development, the status of the clinical trials, and other pertinent proprietary technology, there is no impairment required. During 2020, the Company incurred legal and filing fees of $17,801 associated with a patent application for pharmaceutical compositions and methods for the treatment of thrombosis. The patents are pending. DuraGraft® On December 15, 2019, the Company entered into a contingent asset purchase agreement (the “Agreement”), as amended on March 31, 2020 and May 29, 2020, with Somahlution, LLC, Somahlution, Inc., and Somaceutica, LLC, companies duly organized under the laws of Delaware (collectively, “Somah”) to acquire all of the assets and none of the liabilities of Somah (the “Acquisition”), including DuraGraft®, a one-time intraoperative vascular graft treatment for use in vascular and bypass surgeries that maintains endothelial function and structure, and other related properties. On July 31, 2020, the Company and Somah entered into Amendment No. 3 to the Agreement and the Agreement was finalized. Pursuant to the terms of this amendment, it was agreed that, as part of the Acquisition, the Company would acquire the outstanding capital stock of Somahlution, Inc., held by Somahlution, LLC, rather than the assets of Somahlution, Inc. This change to the Agreement was made to accommodate the European Union (“EU”) requirements with respect to the future manufacturing under Somahlution, Inc. of CE marked products for sale in the EU. In Amendment No. 2, the Company agreed to assume certain payables of Somah related to clinical and medical expenses. These assumed payables were $344,321. It was agreed that the payments on the assumed debts would be recorded as a prepaid royalty against future royalties. As of March 31, 2021 and December 31, 2020, prepaid royalties were $340,969 and $344,321, respectively, and were recorded as a non-current asset. See Note 9. The Company compensated the Somah stockholders as follows: (1) 10,000,000 shares of common stock valued at $1.25 per share (the Company’s stock is thinly traded therefore the value per share was determined by the funding completed on August 3, 2020 which sold 4,610,064 shares of common stock at $1.25 per share, which was the first tranche of a total funding of $7,000,240 (5,600,272 shares, August 3, 2020 and September 25, 2020) which all stock was sold at $1.25 per share); (2) 3,000,000 warrants with a strike price of $5.00 per share and a term of five years; and (3) royalties on all net sales for Somahlution, Inc. of 6% on the first $50 million of net sales, 4% for greater than $50 million up to $200 million, and 2% for greater than $200 million. The Company is in the process of determining the fair value of the royalty component of the total consideration as well as the identifiable intangible assets acquired in business combination. The Company is using a third-party valuation firm and at this time we are unable to estimate the contingent consideration related to the future royalty payment stream amount accurately. The Company is expecting the valuation to be finalized in the Form 10-Q for the period ended June 30, 2021. As such, the following table represents the preliminary consideration in connection with the transaction excluding the fair value of the royalty payment stream: Consideration given: Common stock shares given $ 12,500,000 Warrants given 1,932,300 Total consideration given $ 14,432,300 Fair value of identifiable assets acquired, and liabilities assumed: Receivable $ 45,845 Inventory 229,635 Fixed assets 9,092 Intangible assets 14,147,728 Total identifiable net assets $ 14,432,300 The Company anticipates a significant fair value to be assigned to identifiable intangible assets such as in process research and development and patents. Included in the preliminary allocation to the fair value of assets acquired and liabilities assumed is an 100% allocation to intangible assets for the consideration in excess of tangible net assets. The Company utilized a preliminary estimated weighted average amortization period of seven years. As such, the Company recorded amortization expense of $353,693 for the three months ended March 31, 2021 and $0 for the three months ended March 31, 2020. Dr. Vithal D. Dhaduk, a co-founder of Somahlution, LLC (“Dhaduk”), is the subject of a complaint filed in the United States District Court, Middle District of Pennsylvania, Civil Action No. 3:17 cv 02243 in December 2017 by Mukeshkkumar B. Patel (“Patel”), a former business partner of Dhaduk, which complaint makes claims of breach of contract, promissory estoppel and unjust enrichment regarding a Memorandum of Understanding, dated July 16, 2015, between Patel and Dhaduk (“MOU”). The MOU provided that Dhaduk would pay Patel $9.45 million as consideration for Patel’s agreement to, among other things, (i) exit certain legal entities that were purportedly jointly owned by certain affiliates of Dhaduk and Patel, including Somahlution LLC, and (ii) relinquish his ownership interests in such entities. On December 2, 2019, the court granted Patel’s motion for summary judgment on his breach of contract claim, which judgment Dhaduk is currently appealing (such legal proceedings, collectively referred to as the “Dhaduk Litigation”). The Company is not a named defendant in the Dhaduk Litigation, and the court’s summary judgment is against Dhaduk in his personal capacity.

Commitments and Contingencies

Commitments and Contingencies	3 Months Ended
	Mar. 31, 2021
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	NOTE 6 – COMMITMENTS AND CONTINGENCIES Legal Matters From time to time, we may be involved in litigation relating to claims arising out of our operations in the normal course of business. As of May 6, 2021, there were no pending or threatened lawsuits. Contingencies On July 13, 2019, the Company signed a consulting agreement with an individual to advise the Board of Directors. The individual receives $30,000 per month through July 13, 2022 and received an option to purchase 250,000 shares of common stock at a strike price of $1.50, which vest monthly through July 13, 2021. The vesting of these options was accelerated by the Board on September 2, 2020. See Note 10. The agreement also provided for royalties derived directly from the assets related to wound healing, debridement, grafting, dental applications for both human and pet, and thrombosis (see Note 5 – Krillase). The royalties associated with the acquisition of Krillase will be calculated as follows: Royalties on sales equal to: 10% on net sales On December 15, 2019, the Company entered into the Agreement, as amended on March 31, 2020 and May 29, 2020, with Somah (see Note 5). The royalties associated with the Agreement will be calculated as follows: Royalties on U.S. sales equal to: 5% on the first $50,000,000 of net sales 4% on net sales of $50,000,001 up to $200,000,000 2% on net sales over $200,000,000 Royalties on sales outside of the U.S.: 6% on the first $50,000,000 of net sales 4% on net sales of $50,000,001 up to $200,000,000 2% on net sales over $200,000,000 The royalties are in perpetuity. As of March 31, 2021, there has been no revenue related to the above royalties. The Company, after the acquisition of Somah, has been leasing the office space on a month-to-month basis with a monthly rate of $10,701. The Company maintained this office space through December 31, 2020. Employment and Consulting Agreements On September 1, 2020, Bruce Harmon executed a consulting agreement and was named as chief financial officer. He is compensated $120,000 annually, received 40,000 shares of common stock vesting over one year. On October 22, 2020, Mr. Harmon received 120,000 options for common stock vesting over three years with an exercise price of $1.25. See Note 10. On November 1, 2020, Mr. Harmon became an employee of the Company thereby cancelling the consulting agreement. On March 5, 2021, Mr. Harmon executed a letter of understanding for employment. See Note 1. On November 1, 2020, Dr. Neil J. Campbell executed an employment agreement and was named as chief executive officer, president and director. He is compensated $375,000 annually, received 500,000 options for common stock vesting over three years, with an exercise price of $1.25. On March 18, 2021, Dr. Campbell resigned all positions. See Notes 1 and 12. We expect to enter into a settlement and release agreement with Dr. Campbell but as of the date of this report no such agreement has been finalized. On November 30, 2020, Dr. Steven Brooks executed a letter of understanding for employment as chief medical officer. On December 1, 2020, Dr. Donald Very executed a letter of understanding for employment as executive vice president of research and development. On January 16, 2021, Roger Schaller executed a letter of understanding for employment as executive vice president of commercial operations. Risks and Uncertainties The outbreak of the coronavirus (COVID-19) resulted in increased travel restrictions, and shutdown of businesses, which may cause slower recovery of the economy. We may experience impact from quarantines, market downturns and changes in customer behavior related to pandemic fears and impact on our workforce if the virus continues to spread. In addition, one or more of our customers, partners, service providers or suppliers may experience financial distress, delayed or defaults on payment, file for bankruptcy protection, sharp diminishing of business, or suffer disruptions in their business due to the outbreak. The extent to which the coronavirus impacts our results will depend on future developments and reactions throughout the world, which are highly uncertain and will include emerging information concerning the severity of the coronavirus and the actions taken by governments and private businesses to attempt to contain the coronavirus. It is likely to result in a potential material adverse impact on our business, results of operations and financial condition. Wider-spread COVID-19 globally could prolong the deterioration in economic conditions and could cause decreases in or delays in advertising spending and reduce and/or negatively impact our short-term ability to grow our revenues. Any decreased collectability of accounts receivable, bankruptcy of small and medium businesses, or early termination of agreements due to deterioration in economic conditions could negatively impact our results of operations.

Fixed Assets

Fixed Assets	3 Months Ended
	Mar. 31, 2021
Property, Plant and Equipment [Abstract]
Fixed Assets	NOTE 7 – FIXED ASSETS Fixed assets, stated at cost, less accumulated depreciation at March 31, 2021 and December 31, 2020 consisted of the following: March 31, December 31, 2021 2020 Furniture and equipment $ 701 $ 701 Computer related 7,220 7,220 Machinery and equipment 1,171 1,171 Total 9,092 9,092 Less: accumulation depreciation (4,970 ) (1,970 ) Property and equipment, net $ 4,122 $ 7,122 Depreciation expense for the three months ended March 31, 2021 and 2020 was $3,000 and $0, respectively.

Intangible Assets

Intangible Assets	3 Months Ended
	Mar. 31, 2021
Goodwill and Intangible Assets Disclosure [Abstract]
Intangible Assets	NOTE 8 –INTANGIBLE ASSETS On September 12, 2018, the Company consummated an asset acquisition with ACB Holding AB, Reg. No. 559119-5762, a Swedish corporation to acquire all right, title and interest in their Krillase technology in exchange for 16.98 million shares of common stock. Krillase is a naturally occurring enzyme that acts to break protein bonds and has applications in dental care, wound healing and thrombosis. The transaction was recorded at the fair value of the shares. No amortization has been recorded as the patents and patent applications are not yet in a position to produce cash flows. During 2020, the Company incurred legal and filing fees of $17,801 associated with a patent application for pharmaceutical compositions and methods for the treatment of thrombosis. The patents are pending. The Company capitalized these costs. On July 31, 2020, the Company executed an agreement with Somah (see Note 4) for the DuraGraft® technology in exchange for 10,000,000 shares of common stock, 3,000,000 warrants and a royalty as stated herein. Somah is engaged in developing products to prevent ischemic injury to organs and tissues and DuraGraft® is a one-time intraoperative vascular graft treatment for use in vascular and bypass surgeries that maintains endothelial function and structure, and other related properties. March 31, 2021 December 31, 2020 Gross Net Gross Net Carrying Accumulated Carrying Carrying Accumulated Carrying Amount Amortization Amount Amount Amortization Amount Krillase - Patents, Patent Applications, Research and Development, Clinical Trials, Developed Technology $ 28,600,000 $ - $ 28,600,000 $ 28,600,000 $ - $ 28,600,000 DuraGraft - Patents, Patent Applications, Research and Development, Clinical Trials, Developed Technology 14,147,729 (943,182 ) 13,204,547 14,147,729 (589,489 ) 13,558,240 Patents in process 122,746 - 122,746 119,971 - 119,971 Total Intangibles $ 42,870,475 $ (943,182 ) $ 41,927,293 $ 42,867,700 $ (589,489 ) $ 42,278,211 Balance, December 31, 2019 $ 28,613,000 Acquired in asset purchase agreement 14,147,729 Additions 106,971 Amortization expense (589,489 ) Balance, December 31, 2020 42,278,211 Additions 2,775 Amortization expense (353,693 ) Balance, March 31, 2021 $ 41,927,293 The Company has recorded amortization expense of $353,693 for the three months ended March 31, 2021 and $0 for the three months ended March 31, 2020. The useful lives of the intangible assets are based on the life of the patent and related technology. The patents and related technology for Krillase are not currently being amortized as they have not yet been put into operations. Future amortizations for DuraGraft related intangible assets for the next five years will be $1,414,773 for each year from 2021 through 2026 and $6,484,375 for 2027 and thereafter.

Related Party Transactions

Related Party Transactions	3 Months Ended
	Mar. 31, 2021
Related Party Transactions [Abstract]
Related Party Transactions	NOTE 9 – RELATED PARTY TRANSACTIONS The Company has recorded a prepaid royalty to the shareholders of Somahlution, LLC in regard to the acquisition (see Note 5). The primary beneficial owner is Dr. Vithal Dhaduk, a director of the Company (appointed in 2021) and significant shareholder of the Company. Prepaid royalties were $340,969 at March 31, 2021 and $344,321 at December 31, 2020.

Stockholders' Equity

Stockholders' Equity	3 Months Ended
	Mar. 31, 2021
Equity [Abstract]
Stockholders' Equity	NOTE 10 – STOCKHOLDERS’ EQUITY Preferred stock Our Articles of Incorporation authorize the issuance of 25,000,000 shares of “blank check” preferred stock with a par value of $0.001. As of March 31, 2021, and December 31, 2020, there were no shares issued and outstanding, respectively. Common stock Our Articles of Incorporation authorize the issuance of 75,000,000 shares of common stock with a par value of $0.001. As of March 31, 2021 and December 31, 2020, there were 35,928,188 shares of common stock issued and outstanding. Options On January 13, 2021, the Board of Directors approved the Marizyme, Inc. 2021 Stock Incentive Plan (“SIP”). The SIP incorporates stock options issued prior to January 13, 2021. The SIP authorized 5,300,000 options for issuance. As of March 31, 2021, there remains 512,500 options available for issuance. The summary of option activity for the three months ended March 31, 2021 is as follows: Weighted Weighted Average Average Total Number of Exercise Contractual Instrinic Options Price Life Value Outstanding at December 31, 2020 3,800,943 $ 1.36 Granted 732,500 $ 1.25 Exercised - $ - Forfeited - $ - Outstanding at March 31, 2021 4,533,443 $ 1.35 8.82 $ 123,600 Exercisable at March 31, 2021 2,960,735 $ 1.40 The fair value of each stock option was estimated using the Black Scholes pricing model which takes into account as of the grant date the exercise price (ranging from $1.01 to $1.37 per share in the first quarter of 2021) and expected life of the stock option (10 years in 2021), the current price of the underlying stock and its expected volatility (ranging from 179.31% to 304.44% in the first quarter of 2021), expected dividends (0%) on the stock and the risk-free interest rate (.93%) for the term of the stock option. In addition, the Company recognizes forfeitures as they occur. The fair value of each stock option was estimated using the Black Scholes pricing model which takes into account as of the grant date the exercise price (ranging from $1.01 to $1.37 per share in 2020) and expected life of the stock option (10 years in 2020), the current price of the underlying stock and its expected volatility (ranging from 179.31% to 304.44% in 2020), expected dividends (0%) on the stock and the risk-free interest rate (.93%) for the term of the stock option. In addition, the Company recognizes forfeitures as they occur. The following stock options were granted during the three months ended March 31, 2021: On January 1, 2021, the Company issued 7,500 options for common stock to an employee. The options vest over three years, have an exercise price of $1.25 and expire in 10 years. For the three months ended March 31, 2021, the Company has recorded $708 in stock-based compensation. The Black-Scholes value was determined to be $1.13. As of March 31, 2021, there is an unamortized amount of $7,792. On January 12, 2021, the Company issued 20,000 options for common stock to an employee. The options vest over three years, have an exercise price of $1.25 and expire in 10 years. For the three months ended March 31, 2021, the Company has recorded $1,717 in stock-based compensation. The Black-Scholes value was determined to be $1.19. As of March 31, 2021, there is an unamortized amount of $22,083. On January 16, 2021, the Company issued 40,000 options for common stock to Roger Schaller, the Company’s executive vice president. The options vest over three years, have an exercise price of $1.25 and expire in 10 years. For the three months ended March 31, 2021, the Company has recorded $3,356 in stock-based compensation. The Black-Scholes value was determined to be $1.22. As of March 31, 2021, there is an unamortized amount of $45,640. On January 29, 2021, the Company issued 40,000 options for common stock to Amy Chandler, the Company’s executive vice president. The options vest over three years, have an exercise price of $1.25 and expire in 10 years. For the three months ended March 31, 2021, the Company has recorded $2,745 in stock-based compensation. The Black-Scholes value was determined to be $1.22. As of March 31, 2021, there is an unamortized amount of $45,727. On March 5, 2021, the Company issued 125,000 options for common stock to James Sapirstein, a director of the Company. The options vest over three years, have an exercise price of $1.25 and expire in 10 years. For the three months ended March 31, 2021, the Company has recorded $11,003 in stock-based compensation. The Black-Scholes value was determined to be $1.19. As of March 31, 2021, there is an unamortized amount of $137,747. On March 5, 2021, the Company issued 125,000 options for common stock to Terry Brostowin, a director of the Company. The options vest over three years, have an exercise price of $1.25 and expire in 10 years. For the three months ended March 31, 2021, the Company has recorded $11,003 in stock-based compensation. The Black-Scholes value was determined to be $1.19. As of March 31, 2021, there is an unamortized amount of $137,747. On March 5, 2021, the Company issued 125,000 options for common stock to Dr. William Hearl, a director of the Company. The options vest over three years, have an exercise price of $1.25 and expire in 10 years. For the three months ended March 31, 2021, the Company has recorded $11,003 in stock-based compensation. The Black-Scholes value was determined to be $1.19. As of March 31, 2021, there is an unamortized amount of $137,747. On March 5, 2021, the Company issued 125,000 options for common stock to Julie Kampf, a director of the Company. The options vest over three years, have an exercise price of $1.25 and expire in 10 years. For the three months ended March 31, 2021, the Company has recorded $11,003 in stock-based compensation. The Black-Scholes value was determined to be $1.19. As of March 31, 2021, there is an unamortized amount of $137,747. On March 5, 2021, the Company issued 125,000 options for common stock to Dr. Vithal Dhaduk, a director of the Company. The options vest over three years, have an exercise price of $1.25 and expire in 10 years. For the three months ended March 31, 2021, the Company has recorded $11,003 in stock-based compensation. The Black-Scholes value was determined to be $1.19. As of March 31, 2021, there is an unamortized amount of $137,747. The weighted average grant date fair value of options granted during 2020 was $1.25. As of March 31, 2021, the total unamortized stock-based compensation expense amounted to $1,250,144 and will be expensed through December 2023. As of March 31, 2021, the number of options outstanding and exercisable are as follows including weighted average inputs used in calculating stock-based compensation: Number of Number of Remaining Exercise Options Options Life in Intrinsic Price Outstanding Exercisable Term Years Value $ 1.01 515,000 515,000 10 years 7.69 - 7.78 123,600 $ 1.25 1,622,500 219,792 10 years 9.56 - 9.92 - $ 1.37 200,000 30,000 10 years 9.39 - $ 1.50 2,195,943 2,195,943 10 years 8.29 - 4,533,443 2,960,735 123,600 Warrants As of March 31, 2021 and December 31, 2020, there are 3,393,651 warrants outstanding.

Subsequent Events

Subsequent Events	3 Months Ended
	Mar. 31, 2021
Subsequent Events [Abstract]
Subsequent Events	NOTE 11 - SUBSEQUENT EVENTS The Company has evaluated subsequent events through the date the financial statements were issued and filed with the Securities and Exchange Commission. The Company has determined that there are no other such events that warrant disclosure or recognition in the financial statements, except as stated herein.

Summary of Significant Accoun_2

Summary of Significant Accounting Policies (Policies)	3 Months Ended
	Mar. 31, 2021
Accounting Policies [Abstract]
Basis of Presentation	Basis of Presentation The Company follows the accrual basis of accounting in accordance with generally accepted accounting principles in the United States of America (U.S. GAAP). The unaudited condensed consolidated financial statements of the Company for the three month periods ended March 31, 2021 and 2020 have been prepared in accordance with accounting principles generally accepted in the United States of America for interim financial information and pursuant to the requirements for reporting on Form 10-Q and Regulation S-K. Accordingly, they do not include all the information and footnotes required by accounting principles generally accepted in the United States of America for complete financial statements. However, such information reflects all adjustments (consisting solely of normal recurring adjustments), which are, in the opinion of management, necessary for the fair presentation of the financial position and the results of operations. Results shown for interim periods are not necessarily indicative of the results to be obtained for a full fiscal year. The balance sheet information as of December 31, 2020 was derived from the audited financial statements included in the Company’s financial statements as of and for the year ended December 31, 2020 included in the Company’s Annual Report on Form 10-K filed with the Securities and Exchange Commission (the “SEC”) on April 15, 2021. These financial statements should be read in conjunction with that report.
Principles of Consolidation	Principles of Consolidation The accompanying unaudited condensed consolidated financial statements include all of the accounts of the Company and its wholly owned subsidiaries, Somahlution, Inc. (“Somahlution”), Somaceutica, Inc. (“Somaceutica”) and Marizyme Sciences, Inc. (“Marizyme Sciences”). All significant intercompany balances and transactions have been eliminated.
Use of Estimates	Use of Estimates The preparation of the unaudited condensed consolidated financial statements in accordance with U.S. GAAP requires management to make use of certain estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities as of the date of the consolidated financial statements and the reported amounts of revenue and expenses during the reported periods. The Company bases its estimates on historical experience and on various other assumptions that management believes are reasonable under the circumstances, the results of which form the basis for making judgments about carrying values of assets and liabilities that are not readily apparent from other sources. Actual results could differ from those estimates. Significant estimates are related to the allocation of the purchase price in a business combination to the underlying assets and liabilities, allowance for doubtful accounts, recoverability of long-term assets including intangible assets and goodwill, amortization expense, inventory valuation, valuation of warrants, stock-based compensation, and deferred tax valuations.
Business Combinations	Business Combinations The Company accounts for business acquisitions using the acquisition method of accounting based on Accounting Standards Codification (“ASC”) 805 — Business Combinations, which requires recognition and measurement of all identifiable assets acquired and liabilities assumed at their fair value as of the date control is obtained. The Company determines the fair value of assets acquired and liabilities assumed based upon its best estimates of the acquisition-date fair value of assets acquired and liabilities assumed in the acquisition. Goodwill represents the excess of the purchase price over the fair value of the net tangible and identifiable intangible assets acquired. Subsequent adjustments to fair value of any contingent consideration are recorded to the Company’s consolidated statements of operations.
Stock-Based Compensation	Stock-Based Compensation Stock-based compensation expense is recorded in accordance with FASB ASC Topic 718, Compensation – Stock Compensation, for stock and stock options awarded in return for services rendered. The expense is measured at the grant-date fair value of the award and recognized as compensation expense on a straight-line basis over the service period, which is the vesting period. The Company estimates forfeitures that it expects will occur and records expense based upon the number of awards expected to vest. The fair value of each option is estimated on the date of grant using the Black-Scholes option pricing model.
Cash Equivalents	Cash Equivalents The Company considers all highly liquid investments with an original maturity of three months or less when purchased to be cash equivalents. At March 31, 2021 and December 31, 2020, the Company had no cash equivalents.
Reclassifications	Reclassifications Certain amounts in the prior year’s unaudited condensed consolidated financial statements have been reclassified to conform to the current period presentation. These reclassifications had no effect on reported losses, total assets, or stockholders’ equity as previously reported. The reclassifications were for the Statement of Operation which combined its expenses into two categories whereas, for comparison purposes for the three months ended March 31, 2021 to March 31, 2020, professional fees and stock-based compensation was segregated.
Allowance for Doubtful Accounts	Allowance for Doubtful Accounts The Company establishes an allowance for doubtful accounts to ensure trade and notes receivable are not overstated due to non-collectability. The Company’s allowance is based on a variety of factors, including age of the receivable, significant one-time events, historical experience, and other risk considerations. The Company did not have an allowance at March 31, 2021 or December 31, 2020. The Company did not record any bad debt expense in each of the three months ended March 31, 2021 and 2020.
Inventory	Inventory Inventory consisted of primarily finished goods and is valued at the lower of cost or net realizable value. Inventory is held in a third-party warehouse in foreign countries. Cost is determined using the FIFO method. The Company decreases the value of inventory for estimated obsolescence equal to the difference between the cost of inventory and the estimated market value, based upon an aging analysis of the inventory on hand, specifically known inventory-related risks, and assumptions about future demand and market conditions. The Company has determined that no inventory reserve was necessary as of March 31, 2021 and December 31, 2020.
Fair Value of Financial Instruments	Fair Value of Financial Instruments The Company measures its financial assets and liabilities in accordance with FASB ASC 820 (the “Fair Value Topic”). For certain of our financial instruments, including cash, accounts payable, accrued expenses, and short-term loans the carrying amounts approximate fair value due to their short maturities. We follow accounting guidance for financial and non-financial assets and liabilities. This standard defines fair value, provides guidance for measuring fair value and requires certain disclosures. This standard does not require any new fair value measurements, but rather applies to all other accounting pronouncements that require or permit fair value measurements. This guidance does not apply to measurements related to share-based payments. This guidance discusses valuation techniques, such as the market approach (comparable market prices), the income approach (present value of future income or cash flow), and the cost approach (cost to replace the service capacity of an asset or replacement cost). The guidance utilizes a fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value into three broad levels. The following is a brief description of those three levels: Level 1: Observable inputs such as quoted prices (unadjusted) in active markets for identical assets or liabilities. Level 2: Inputs other than quoted prices that are observable, either directly or indirectly. These include quoted prices for similar assets or liabilities in active markets and quoted prices for identical or similar assets or liabilities in markets that are not active. Level 3: Unobservable inputs in which little or no market data exists, therefore developed using estimates and assumptions developed by us, which reflect those that a market participant would use. The Company had no assets or liabilities measured at fair value on a recurring basis at March 31, 2021 and December 31, 2020.
Fixed Assets	Fixed Assets Fixed assets are recorded at cost. Expenditures for major additions and betterments are capitalized. Maintenance and repairs are charged to operations as incurred. Depreciation is computed by the straight-line method over the assets estimated useful life. Upon the sale or retirement of property and equipment, the related cost and accumulated depreciation are removed from the accounts and any gain or loss is reflected in consolidated statements of operations. Classification Estimated Useful Lives Equipment 5 to 7 years Furniture and fixtures 4 to 7 years
Intangible Assets	Intangible Assets Costs incurred to file patent applications and acquired intangibles are capitalized when the Company believes that there is a high likelihood that the patent will be issued and there will be future economic benefit associated with the patent. These costs will be amortized on a straight-line basis over a 20-year life from the date of patent filing. All costs associated with abandoned patent applications are expensed. In addition, the Company will review the carrying value of patents for indicators of impairment on a periodic basis and if it determines that the carrying value is impaired, it values the patent at fair value. As of March 31, 2021, $122,746 has been capitalized for patents which have not been amortized.
Impairment of Long-lived Assets	Impairment of Long-lived Assets The Company follows ASC 360 for its long-lived assets. The Company’s long-lived assets, such as intellectual property, are required to be reviewed for impairment annually, or whenever events or changes in circumstances indicate that the carrying amount of the asset may not be recoverable. The Company assesses the recoverability of its long-lived assets by comparing the projected undiscounted net cash flows associated with the related long-lived asset or group of long-lived assets over their remaining estimated useful lives against their respective carrying amounts. Impairment, if any, is based on the excess of the carrying amount over the fair value of those assets. Fair value is generally determined using the asset’s expected future discounted cash flows or market value, if readily determinable. If long-lived assets are determined to be recoverable, but the newly determined remaining estimated useful lives are shorter than originally estimated, the net book values of the long-lived assets are depreciated over the newly determined remaining estimated useful lives. The Company determined that there were no impairments of long-lived assets at March 31, 2021 and December 31, 2020.
Revenue Recognition	Revenue Recognition We recognize revenue under Accounting Standards Codification (“ASC”) 606, Revenue from Contracts with Customers, (“ASC 606”). The core principle of the revenue standard is that a company should recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which we expect to be entitled in exchange for those goods or services. We only apply the five-step model to contracts when it is probable that we will collect the consideration to which we are entitled in exchange for the goods and services transferred to the customer. The following five steps are applied to achieve that core principle: Step 1: Identify the contract with the customer Step 2: Identify the performance obligations in the contract Step 3: Determine the transaction price Step 4: Allocate the transaction price to the performance obligations in the contract Step 5: Recognize revenue when the company satisfies a performance obligation We have identified one performance obligation which is related to our DuraGraft product sales for our Distribution Partner channel, we recognize revenue for product sales at the time of delivery of the product to our Distribution Partner (customer). The customer is invoiced, and Payment Terms are Net 30. As our products have an expiration date, if a product expires before use, we will replace the product on the shelf at no charge. Revenue disaggregation for three months ended March 31, 2021 amount to $54,319 in Spain, $6,730 in Singapore, $8,656 in Switzerland and $4,247 in India. In the transaction that acquired the assets of Somahlution, LLC, the Company determined that the CE mark for Europe must be in Marizyme, Inc. in order for Somahlution, Inc. to bill revenue and receive the payments accordingly. The Company has filed in Europe for the CE mark to be in Marizyme, Inc. but, until the time it is approved by the Notified Body, BSI (British Standards Institution), which is projected for May 2021, Somahlution, LLC provides the billing and receiver of funds. On a periodical basis, the cash received is transferred to Somahlution, Inc.
Direct Cost of Revenue	Direct Cost of Revenue Cost of sales includes the actual cost of merchandise sold; the cost of transportation of merchandise from our third-party vendor to our distributer.
Net Income (Loss) Per Share	Net Income (Loss) per Share The Company computes basic and diluted income (loss) per share amounts pursuant to ASC 260 of the FASB Accounting Standards Codification. Basic loss per share is computed by dividing net loss available to common stockholders, by the weighted average number of shares of common stock outstanding during the period, excluding the effects of any potentially dilutive securities. Diluted loss per share is computed by dividing net loss available to common stockholders by the diluted weighted average number of shares of common stock during the period. The diluted weighted average number of common shares outstanding is the basic weighted number of shares adjusted as of the first day of the year for any potentially diluted debt or equity. The following is a reconciliation of basic and diluted earnings (loss) per common share for the three months ended March 31, 2021 and 2020: For the Three Months Ended March 31, 2021 2020 Basic and diluted loss per common share Numerator: Net loss available to common shareholders $ (2,846,119 ) $ (471,370 ) Denominator: Weighted average common shares outstanding 35,928,188 19,887,021 Basic and diluted loss per common share $ (0.08 ) $ (0.02 )
Income Taxes	Income Taxes The Company accounts for income taxes in accordance with FASB ASC 740, “Income Taxes.” Deferred tax assets and liabilities are recognized for the future tax consequences attributable to temporary differences between the financial statements carrying amounts of existing assets and liabilities and loss carryforwards and their respective tax bases. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income (loss) in the years in which those temporary differences are expected to be recovered or settled. The effect of a change in tax rules on deferred tax assets and liabilities is recognized in operations in the year of change. A valuation allowance is recorded when it is “more likely-than-not” that a deferred tax asset will not be realized. Tax benefits of uncertain tax positions are recognized only if it is more likely than not that the Company will be able to sustain a position taken on an income tax return. The Company has no liability for uncertain tax positions as of March 31, 2021 and December 31, 2020. Interest and penalties, if any, related to unrecognized tax benefits would be recognized as interest expense. The Company does not have any accrued interest or penalties associated with unrecognized tax benefits, nor was any significant interest expense recognized during the three months ended March 31, 2021 and 2020.
Segment Information	Segment Information In accordance with the provisions of ASC 280-10, “Disclosures about Segments of an Enterprise and Related Information,” the Company is required to report financial and descriptive information about its reportable operating segments. The Company has one operating segment as of March 31, 2021 and December 31, 2020.
Effect of Recent Accounting Pronouncements	Effect of Recent Accounting Pronouncements Recently Issued Accounting Standards Not Yet Adopted The Company has reviewed all recently issued, but not yet adopted, accounting standards, in order to determine their effects, if any, on its results of operations, financial position or cash flows. Based on that review, the Company believes that no other pronouncements will have a significant effect on its consolidated financial statements.
Concentration of Credit Risk	Concentration of Credit Risk The Company places its temporary cash investments with financial institutions insured by the FDIC. The Company has amounts over insured limits. Amounts on deposit may at times exceed the FDIC insurance limit. The Company has not experienced any losses in such accounts.
Customer Concentrations	Customer Concentrations For the three months ended March 31, 2021, four customers/distributors selling to end customers made up 100% of the revenues. As of March 31, 2021, three customers/distributors made up 100% of accounts receivable.
Research and Development	Research and Development All research and development costs, payments to laboratories and research consultants are expensed when incurred.

Summary of Significant Accoun_3

Summary of Significant Accounting Policies (Tables)	3 Months Ended
	Mar. 31, 2021
Accounting Policies [Abstract]
Schedule of Useful Life of Fixed Assets	Classification Estimated Useful Lives Equipment 5 to 7 years Furniture and fixtures 4 to 7 years
Schedule of Reconciliation of Basic and Diluted Earnings (Loss)	The following is a reconciliation of basic and diluted earnings (loss) per common share for the three months ended March 31, 2021 and 2020: For the Three Months Ended March 31, 2021 2020 Basic and diluted loss per common share Numerator: Net loss available to common shareholders $ (2,846,119 ) $ (471,370 ) Denominator: Weighted average common shares outstanding 35,928,188 19,887,021 Basic and diluted loss per common share $ (0.08 ) $ (0.02 )

Lease (Tables)

Lease (Tables)	3 Months Ended
	Mar. 31, 2021
Leases [Abstract]
Schedule of Right-of-Use Asset and Related Lease Liability	As a result, the value of the right-of-use asset and related lease liability is as follows: March 31, December 31, 2021 2020 Right-of-use asset $ 1,257,929 $ 1,317,830 Total lease liability $ 1,282,262 $ 1,317,830 Less: Current portion 304,114 243,292 Lease liability, net of current portion $ 978,148 $ 1,074,538
Schedule of Maturities of Lease Liabilities	The maturities of the lease liabilities are as follows as of March 31, 2021 for the periods ended December 31: 2021 $ 156,748 2022 277,142 2023 277,142 2024 277,142 2025 277,142 Thereafter 130,950 Total lease payments 1,396,266 Less: Present value discount (114,004 ) Total $ 1,282,262

Acquisitions (Tables)

Acquisitions (Tables)	3 Months Ended
	Mar. 31, 2021
Business Combinations [Abstract]
Schedule of Preliminary Allocation of Consideration	As such, the following table represents the preliminary consideration in connection with the transaction excluding the fair value of the royalty payment stream: Consideration given: Common stock shares given $ 12,500,000 Warrants given 1,932,300 Total consideration given $ 14,432,300 Fair value of identifiable assets acquired, and liabilities assumed: Receivable $ 45,845 Inventory 229,635 Fixed assets 9,092 Intangible assets 14,147,728 Total identifiable net assets $ 14,432,300

Fixed Assets (Tables)

Fixed Assets (Tables)	3 Months Ended
	Mar. 31, 2021
Property, Plant and Equipment [Abstract]
Schedule of Property, Plant, and Equipment	Fixed assets, stated at cost, less accumulated depreciation at March 31, 2021 and December 31, 2020 consisted of the following: March 31, December 31, 2021 2020 Furniture and equipment $ 701 $ 701 Computer related 7,220 7,220 Machinery and equipment 1,171 1,171 Total 9,092 9,092 Less: accumulation depreciation (4,970 ) (1,970 ) Property and equipment, net $ 4,122 $ 7,122

Intangible Assets (Tables)

Intangible Assets (Tables)	3 Months Ended
	Mar. 31, 2021
Goodwill and Intangible Assets Disclosure [Abstract]
Summary of Intangible Assets Amortization Expense	March 31, 2021 December 31, 2020 Gross Net Gross Net Carrying Accumulated Carrying Carrying Accumulated Carrying Amount Amortization Amount Amount Amortization Amount Krillase - Patents, Patent Applications, Research and Development, Clinical Trials, Developed Technology $ 28,600,000 $ - $ 28,600,000 $ 28,600,000 $ - $ 28,600,000 DuraGraft - Patents, Patent Applications, Research and Development, Clinical Trials, Developed Technology 14,147,729 (943,182 ) 13,204,547 14,147,729 (589,489 ) 13,558,240 Patents in process 122,746 - 122,746 119,971 - 119,971 Total Intangibles $ 42,870,475 $ (943,182 ) $ 41,927,293 $ 42,867,700 $ (589,489 ) $ 42,278,211
Schedule of Intangible Assets	Balance, December 31, 2019 $ 28,613,000 Acquired in asset purchase agreement 14,147,729 Additions 106,971 Amortization expense (589,489 ) Balance, December 31, 2020 42,278,211 Additions 2,775 Amortization expense (353,693 ) Balance, March 31, 2021 $ 41,927,293

Stockholders' Equity (Tables)

Stockholders' Equity (Tables)	3 Months Ended
	Mar. 31, 2021
Equity [Abstract]
Schedule of Stock Option Activity	The summary of option activity for the three months ended March 31, 2021 is as follows: Weighted Weighted Average Average Total Number of Exercise Contractual Instrinic Options Price Life Value Outstanding at December 31, 2020 3,800,943 $ 1.36 Granted 732,500 $ 1.25 Exercised - $ - Forfeited - $ - Outstanding at March 31, 2021 4,533,443 $ 1.35 8.82 $ 123,600 Exercisable at March 31, 2021 2,960,735 $ 1.40
Schedule of Options Outstanding and Exercisable	As of March 31, 2021, the number of options outstanding and exercisable are as follows including weighted average inputs used in calculating stock-based compensation: Number of Number of Remaining Exercise Options Options Life in Intrinsic Price Outstanding Exercisable Term Years Value $ 1.01 515,000 515,000 10 years 7.69 - 7.78 123,600 $ 1.25 1,622,500 219,792 10 years 9.56 - 9.92 - $ 1.37 200,000 30,000 10 years 9.39 - $ 1.50 2,195,943 2,195,943 10 years 8.29 - 4,533,443 2,960,735 123,600

Organization and Description _2

Organization and Description of Business (Details Narrative) - $ / shares	Sep. 12, 2018	Mar. 31, 2021	Dec. 31, 2020	Jun. 01, 2018
Common stock, par value		$ 0.001	$ 0.001
Krillase Technology [Member]
Issuance of common stock for acquisition, shares	16,980,000
X- Assets Enterprises, Inc [Member]
Equity ownership method, percentage				100.00%

Going Concern (Details Narrativ

Going Concern (Details Narrative) - USD ($)	3 Months Ended
	Mar. 31, 2021	Mar. 31, 2020	Dec. 31, 2020
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Net loss	$ (2,810,551)	$ (471,370)
Cash used in operating activities	(2,065,030)	$ (30)
Working capital surplus	229,297
Accumulated deficit	$ (39,636,185)		$ (36,825,634)

Summary of Significant Accoun_4

Summary of Significant Accounting Policies (Details Narrative)	3 Months Ended
	Mar. 31, 2021USD ($)Segment	Mar. 31, 2020USD ($)	Dec. 31, 2020USD ($)
Cash equivalents
Allowance for doubtful accounts
Bad debt expense
Inventory reserve
Assets or liabilities measured at fair value on a recurring basis
Intangible assets useful life	20 years
Impairment of long-lived assets
Revenue	$ 73,952
Number of operating segment | Segment	1
Amortization	$ 353,693	$ 0
Patents [Member]
Amortization	$ 122,746
Revenue [Member] | Customer Concentration Risk [Member] | Four Customer [Member]
Concentration risk, percentage	100.00%
Accounts Receivable [Member] | Customer Concentration Risk [Member] | Three Customer [Member]
Concentration risk, percentage	100.00%
Spain [Member]
Revenue	$ 54,319
Singapore [Member]
Revenue	6,730
Switzerland [Member]
Revenue	8,656
India [Member]
Revenue	$ 4,247

Summary of Significant Accoun_5

Summary of Significant Accounting Policies - Schedule of Useful Life of Fixed Assets (Details)	3 Months Ended
	Mar. 31, 2021
Equipment [Member] | Minimum [Member]
Estimated useful lives	5 years
Equipment [Member] | Maximum [Member]
Estimated useful lives	7 years
Furniture and Fixtures [Member] | Minimum [Member]
Estimated useful lives	4 years
Furniture and Fixtures [Member] | Maximum [Member]
Estimated useful lives	7 years

Summary of Significant Accoun_6

Summary of Significant Accounting Policies - Schedule of Reconciliation of Basic and Diluted Earnings (Loss) (Details) - USD ($)	3 Months Ended
	Mar. 31, 2021	Mar. 31, 2020
Accounting Policies [Abstract]
Basic and diluted loss per common share: Net loss available to common shareholders	$ (2,810,551)	$ (471,370)
Basic and diluted loss per common share: Weighted average common shares outstanding	35,928,188	19,887,021
Basic and diluted loss per common share	$ (0.08)	$ (0.02)

Lease (Details Narrative)

Lease (Details Narrative) - USD ($)	3 Months Ended
	Mar. 31, 2021	Mar. 31, 2020	Dec. 31, 2020
Operating expenses	$ 2,884,503	$ 471,370
Operating lease, payments	$ 35,568
Operating Lease Agreement [Member]
Operating lease description	The Company entered into an agreement in December 2020 for approximately 8,500 square feet with is for a five-and-one-half year period.
Base rent	$ 10,817
Operating expenses	$ 12,000
Base rent percentage	2.50%
Operating lease discount rate			3.95%

Lease - Schedule of Right-of-Us

Lease - Schedule of Right-of-Use Asset and Related Lease Liability (Details) - USD ($)	Mar. 31, 2021	Dec. 31, 2020
Leases [Abstract]
Right-of-use asset	$ 1,257,929	$ 1,317,830
Total lease liability	1,282,262	1,317,830
Less: Current portion	304,114	243,292
Lease liability, net of current portion	$ 978,148	$ 1,074,538

Lease - Schedule of Maturities

Lease - Schedule of Maturities of Lease Liabilities (Details) - USD ($)	Mar. 31, 2021	Dec. 31, 2020
Leases [Abstract]
2021	$ 156,748
2022	277,142
2023	277,142
2024	277,142
2025	277,142
Thereafter	130,950
Total lease payments	1,396,266
Less: Present value discount	114,004
Total	$ 1,282,262	$ 1,317,830

Acquisitions (Details Narrative

Acquisitions (Details Narrative) - USD ($)	Sep. 25, 2020	Aug. 03, 2020	Jul. 31, 2020	Sep. 12, 2018	Mar. 31, 2021	Mar. 31, 2020	Dec. 31, 2020
Legal and filing fees					$ 17,801
Prepaid royalties, non-current					$ 340,969		$ 344,321
Shares issues at common stock value						$ 125,000
Royalties percentage					10.00%
Net sales					$ 73,952
Percentage of allocation to intangible assets					100.00%
Amortization expense					$ 353,693	$ 0
Consideration transferred amount					14,432,300
Mukeshkkumar B. Patel [Member]
Consideration transferred amount					$ 9,450,000
Krillase Technology [Member]
Issuance of common stock for acquisition, shares				16,980,000
Acquisitions, value				$ 28,600,000
Legal and filing fees							$ 17,801
Somah [Member]
Number of shares issues at common stock	5,600,272	5,600,272	10,000,000
Shares issued, price per share	$ 1.25	$ 1.25	$ 1.25
Sale of common stock, shares		4,610,064
Shares issues at common stock value	$ 7,000,240	$ 7,000,240
Warrant, shares			3,000,000
Warrant, per shares			$ 5
Warrant, term			5 years
Business combination, description			The Company compensated the Somah stockholders as follows: (1) 10,000,000 shares of common stock valued at $1.25 per share (the Company's stock is thinly traded therefore the value per share was determined by the funding completed on August 3, 2020 which sold 4,610,064 shares of common stock at $1.25 per share, which was the first tranche of a total funding of $7,000,240 (5,600,272 shares, August 3, 2020 and September 25, 2020) which all stock was sold at $1.25 per share); (2) 3,000,000 warrants with a strike price of $5.00 per share and a term of five years; and (3) royalties on all net sales for Somahlution, Inc. of 6% on the first $50 million of net sales, 4% for greater than $50 million up to $200 million, and 2% for greater than $200 million.
Somahlution Inc [Member] | Net Sales [Member]
Royalties percentage			6.00%
Net sales			$ 50,000,000
Somahlution Inc [Member] | Net Sales [Member] | Minimum [Member]
Royalties percentage			4.00%
Net sales			$ 50,000,000
Somahlution Inc [Member] | Net Sales [Member] | Maximum [Member]
Royalties percentage			4.00%
Net sales			$ 200,000,000
Somahlution Inc [Member] | Net Sales [Member] | Maximum [Member]
Royalties percentage			2.00%
Net sales			$ 200,000,000

Acquisitions - Schedule of Prel

Acquisitions - Schedule of Preliminary Allocation of Consideration (Details)	3 Months Ended
	Mar. 31, 2021USD ($)
Business Combinations [Abstract]
Common stock shares given	$ 12,500,000
Warrants given	1,932,300
Total consideration given	14,432,300
Receivable	45,845
Inventory	229,635
Fixed assets	9,092
Intangible assets	14,147,728
Total identifiable net assets	$ 14,432,300

Commitments and Contingencies (

Commitments and Contingencies (Details Narrative) - USD ($)	Nov. 01, 2020	Oct. 22, 2020	Sep. 01, 2020	Jul. 13, 2019	Mar. 31, 2021	Mar. 31, 2020
Salary and wage					$ 1,036,457
Issuance of stock options					732,500
Royalties percentage					10.00%
Leasing for office space					$ 10,701
Vesting period					8 years 9 months 25 days
Exercise price per share					$ 1.40
Employment and Consulting Agreements [Member] | Chief Financial Officer [Member]
Issuance of stock options		120,000	40,000
Compensation			$ 120,000
Vesting period		3 years	1 year
Exercise price per share		$ 1.25
Employment and Consulting Agreements [Member] | Chief Executive Officer [Member]
Issuance of stock options	500,000
Compensation	$ 375,000
Vesting period	3 years
Exercise price per share	$ 1.25
US Sales [Member] | First 50,000,000 [Member]
Royalties percentage					5.00%
US Sales [Member] | 50,000,000 Up to 200,000,000 [Member]
Royalties percentage					4.00%
US Sales [Member] | Over 200,000,000 [Member]
Royalties percentage					2.00%
US Outside Sales [Member] | First 50,000,000 [Member]
Royalties percentage					6.00%
US Outside Sales [Member] | 50,000,000 Up to 200,000,000 [Member]
Royalties percentage					4.00%
US Outside Sales [Member] | Over 200,000,000 [Member]
Royalties percentage					2.00%
July 13, 2022 [Member]
Salary and wage				$ 30,000
Issuance of stock options				250,000
July 13, 2021 [Member]
Shares issued, price per share				$ 1.50

Fixed Assets (Details Narrative

Fixed Assets (Details Narrative) - USD ($)	3 Months Ended
	Mar. 31, 2021	Mar. 31, 2020
Property, Plant and Equipment [Abstract]
Depreciation expense	$ 3,000	$ 0

Fixed Assets - Schedule of Prop

Fixed Assets - Schedule of Property, Plant, and Equipment (Details) - USD ($)	Mar. 31, 2021	Dec. 31, 2020
Property and equipment, gross	$ 9,092	$ 9,092
Less: accumulation depreciation	(4,970)	(1,970)
Property and equipment, net	4,122	7,122
Furniture and Equipment [Member]
Property and equipment, gross	701	701
Computer Related [Member]
Property and equipment, gross	7,220	7,220
Machinery and Equipment [Member]
Property and equipment, gross	$ 1,171	$ 1,171

Intangible Assets (Details Narr

Intangible Assets (Details Narrative) - USD ($)	Jul. 31, 2020	Sep. 12, 2018	Mar. 31, 2021	Mar. 31, 2020
Legal and filing fees			$ 17,801
Amortization expense			353,694
Somah [Member]
Number of shares issues at common stock	10,000,000
Warrant, shares	3,000,000
Future amortizations from 2021 through 2028			1,414,773
Future amortizations for 2027			$ 6,484,375
Krillase Technology [Member]
Issuance of common stock for acquisition, shares		16,980,000

Intangible Assets - Summary of

Intangible Assets - Summary of Intangible Assets Amortization Expense (Details) - USD ($)	Mar. 31, 2021	Dec. 31, 2020
Gross Carrying Amount	$ 42,870,475	$ 42,867,700
Amortization expense	(943,182)	(589,489)
Net Carrying Amount	41,927,293	42,278,211
Krillase - Patents, Patent Applications, Research and Development, Clinical Trials, Developed Technology [Member]
Gross Carrying Amount	28,600,000	28,600,000
Amortization expense
Net Carrying Amount	28,600,000	28,600,000
DuraGraft - Patents, Patent Applications, Research and Development, Clinical Trials, Developed Technology [Member]
Gross Carrying Amount	14,147,729	14,147,729
Amortization expense	(943,182)	(589,489)
Net Carrying Amount	13,204,547	13,558,240
Patents in Process [Member]
Gross Carrying Amount	122,746	119,971
Amortization expense
Net Carrying Amount	$ 122,746	$ 119,971

Intangible Assets - Schedule of

Intangible Assets - Schedule of Intangible Assets (Details) - USD ($)	3 Months Ended	12 Months Ended
	Mar. 31, 2021	Dec. 31, 2020
Goodwill and Intangible Assets Disclosure [Abstract]
Beginning Balance	$ 42,278,211	$ 28,613,000
Acquired in asset purchase agreement		14,147,729
Additions	2,775	106,971
Amortization expense	(353,693)	(589,489)
Ending Balance	$ 41,927,293	$ 42,278,211

Related Party Transactions (Det

Related Party Transactions (Details Narrative) - USD ($)	Mar. 31, 2021	Dec. 31, 2020
Related Party Transactions [Abstract]
Prepaid royalties	$ 340,969	$ 344,321

Stockholders' Equity (Details N

Stockholders' Equity (Details Narrative) - USD ($)	Mar. 05, 2021	Jan. 29, 2021	Jan. 16, 2021	Jan. 13, 2021	Jan. 13, 2021	Jan. 02, 2021	Mar. 31, 2021	Dec. 31, 2020	Dec. 30, 2020
Preferred stock, shares authorized							25,000,000	25,000,000
Preferred stock, par value per share							$ 0.001	$ 0.001
Preferred stock, shares issued							0	0
Preferred stock, shares outstanding							0	0
Common stock, par value per share							$ 0.001	$ 0.001
Common stock, shares authorized							75,000,000	75,000,000
Common stock, shares, issued							35,928,188	35,928,188
Common stock, shares, outstanding							35,928,188	35,928,188
Stock issued for exercised of options
Expected life							10 years	10 years
Expected volatility rate minimum							179.31%	179.31%
Expected volatility rate maximum							304.44%	304.44%
Expected dividends rate							0.00%	0.00%
Risk-free interest rate							0.93%	0.93%
Stock option exercise price per share							$ 1.40
Stock based compensation expenses							$ 1,250,144
Weighted average grant date fair value of options granted							$ 1.25
Warrants outstanding							3,393,651	1,393,651
Common Stock [Member] | Employee [Member]
Stock issued for exercised of options				20,000		7,500
Stock option exercise price per share				$ 1.25	$ 1.25	$ 1.25
Stock-based payment award vesting period				3 years		3 years
Stock option expiration period				10 years		10 years
Stock based compensation expenses							$ 708
Share based payment award, fair value							$ 1.13
Unamortized amount of stock option							$ 7,792
Common Stock [Member] | Employee Two [Member]
Stock based compensation expenses							$ 1,717
Share based payment award, fair value							$ 1.19
Unamortized amount of stock option							$ 22,083
Common Stock [Member] | Roger Schaller [Member]
Stock issued for exercised of options			40,000
Stock option exercise price per share			$ 1.25
Stock-based payment award vesting period			3 years
Stock option expiration period			10 years
Stock based compensation expenses							$ 3,356
Share based payment award, fair value							$ 1.22
Unamortized amount of stock option							$ 45,640
Common Stock [Member] | Amy Chandler [Member]
Stock issued for exercised of options		40,000
Stock option exercise price per share		$ 1.25
Stock-based payment award vesting period		3 years
Stock option expiration period		10 years
Stock based compensation expenses							$ 2,745
Share based payment award, fair value							$ 1.22
Unamortized amount of stock option							$ 45,727
Common Stock [Member] | James Sapirstein [Member]
Stock issued for exercised of options	125,000
Stock option exercise price per share	$ 1.25
Stock-based payment award vesting period	3 years
Stock option expiration period	10 years
Stock based compensation expenses							$ 11,003
Share based payment award, fair value							$ 1.19
Unamortized amount of stock option							$ 137,747
Common Stock [Member] | Terry Brostowin [Member]
Stock issued for exercised of options	125,000
Stock option exercise price per share	$ 1.25
Stock-based payment award vesting period	10 years
Stock based compensation expenses							$ 11,003
Share based payment award, fair value							$ 1.19
Unamortized amount of stock option							$ 137,747
Common Stock [Member] | Dr. William Hearl [Member]
Stock issued for exercised of options	125,000
Stock option exercise price per share	$ 1.25
Stock-based payment award vesting period	3 years
Stock option expiration period	10 years
Stock based compensation expenses							$ 11,003
Share based payment award, fair value							$ 1.19
Unamortized amount of stock option							$ 137,747
Common Stock [Member] | Julie Kampf [Member]
Stock issued for exercised of options	125,000
Stock option exercise price per share	$ 1.25
Stock-based payment award vesting period	3 years
Stock option expiration period	10 years
Stock based compensation expenses							$ 11,003
Share based payment award, fair value							$ 1.19
Unamortized amount of stock option							$ 137,747
Common Stock [Member] | Dr. Vithal Dhaduk [Member]
Stock issued for exercised of options	125,000
Stock option exercise price per share	$ 1.25
Stock-based payment award vesting period	3 years
Stock option expiration period	10 years
Stock based compensation expenses							$ 11,003
Share based payment award, fair value							$ 1.19
Unamortized amount of stock option							$ 137,747
Minimum [Member]
Exercise price							$ 1.01		$ 1.01
Maximum [Member]
Exercise price							$ 1.37		$ 1.37
Stock Incentive Plan [Member]
Stock issued for exercised of options					5,300,000		512,500

Stockholders' Equity - Schedule

Stockholders' Equity - Schedule of Stock Option Activity (Details)	3 Months Ended
	Mar. 31, 2021USD ($)$ / sharesshares
Equity [Abstract]
Number of Options, Outstanding Beginning Balance | shares	3,800,943
Number of Options, Granted | shares	732,500
Number of Options, Exercised | shares
Number of Options, Forfeited | shares
Number of Options, Outstanding Ending Balance | shares	4,533,443
Number of Options, Exercisable | shares	2,960,735
Weighted Average Exercise Price, Outstanding Beginning Balance | $ / shares	$ 1.36
Weighted Average Exercise Price, Granted | $ / shares	1.25
Weighted Average Exercise Price, Exercised | $ / shares
Weighted Average Exercise Price, Forfeited | $ / shares
Weighted Average Exercise Price, Outstanding Ending Balance | $ / shares	1.35
Weighted Average Exercise Price, Exercisable | $ / shares	$ 1.40
Weighted Average Contractual Term, Outstanding Ending Balance	8 years 9 months 25 days
Total Intrinsic Value, Ending Balance | $	$ 123,600

Stockholders' Equity - Schedu_2

Stockholders' Equity - Schedule of Options Outstanding and Exercisable (Details) - USD ($)	3 Months Ended
	Mar. 31, 2021	Dec. 31, 2020
Number of Options Outstanding	4,533,443	3,800,943
Number of Options Exercisable	2,960,735
Intrinsic Value	$ 123,600
Exercise Price Range at 1.01 [Member]
Exercise Price	$ 1.01
Number of Options Outstanding	515,000
Number of Options Exercisable	515,000
Term	P10Y
Intrinsic Value	$ 123,600
Exercise Price Range at 1.01 [Member] | Minimum [Member]
Remaining Life in Years	7 years 8 months 9 days
Exercise Price Range at 1.01 [Member] | Maximum [Member]
Remaining Life in Years	7 years 9 months 11 days
Exercise Price Range at 1.25 [Member]
Exercise Price	$ 1.25
Number of Options Outstanding	1,622,500
Number of Options Exercisable	219,792
Term	P10Y
Intrinsic Value
Exercise Price Range at 1.25 [Member] | Minimum [Member]
Remaining Life in Years	9 years 6 months 21 days
Exercise Price Range at 1.25 [Member] | Maximum [Member]
Remaining Life in Years	9 years 11 months 1 day
Exercise Price Range at 1.37 [Member]
Exercise Price	$ 1.37
Number of Options Outstanding	200,000
Number of Options Exercisable	30,000
Term	P10Y
Remaining Life in Years	9 years 4 months 20 days
Intrinsic Value
Exercise Price Range at 1.50 [Member]
Exercise Price	$ 1.50
Number of Options Outstanding	2,195,943
Number of Options Exercisable	2,195,943
Term	P10Y
Remaining Life in Years	8 years 3 months 15 days
Intrinsic Value